© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Surrozen, Inc. (SRZN) stock surged +0.31%, trading at $25.68 on NASDAQ, up from the previous close of $25.60. The stock opened at $25.39, fluctuating between $25.07 and $25.90 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Mar 18, 2026 | 25.39 | 25.98 | 25.00 | 25.68 | 57.91K |
| Mar 17, 2026 | 26.28 | 27.91 | 25.30 | 25.60 | 94.76K |
| Mar 16, 2026 | 25.43 | 25.86 | 24.50 | 25.50 | 33.76K |
| Mar 13, 2026 | 26.41 | 27.81 | 23.43 | 25.21 | 164.01K |
| Mar 12, 2026 | 26.95 | 26.98 | 24.50 | 25.90 | 67.39K |
| Mar 11, 2026 | 28.49 | 28.57 | 26.24 | 26.96 | 59.71K |
| Mar 10, 2026 | 27.67 | 29.47 | 26.15 | 27.74 | 101.01K |
| Mar 09, 2026 | 26.37 | 27.67 | 24.10 | 27.40 | 49.16K |
| Mar 06, 2026 | 27.73 | 29.46 | 26.03 | 27.04 | 122.46K |
| Mar 03, 2026 | 28.31 | 28.45 | 26.00 | 26.85 | 67.41K |
| Mar 02, 2026 | 27.73 | 29.15 | 26.37 | 28.60 | 52.73K |
| Feb 27, 2026 | 25.32 | 27.92 | 25.32 | 27.80 | 47.08K |
| Feb 26, 2026 | 27.27 | 27.27 | 23.63 | 25.75 | 61.04K |
| Feb 25, 2026 | 27.22 | 27.22 | 25.90 | 27.03 | 43.58K |
| Feb 24, 2026 | 26.23 | 27.69 | 26.23 | 27.00 | 40.72K |
| Feb 23, 2026 | 26.59 | 27.91 | 26.18 | 26.58 | 92.28K |
| Feb 20, 2026 | 27.05 | 27.05 | 25.50 | 26.59 | 42.35K |
| Feb 19, 2026 | 25.96 | 27.96 | 25.60 | 26.93 | 91.63K |
| Feb 18, 2026 | 24.73 | 26.84 | 24.38 | 25.09 | 81.26K |
| Feb 17, 2026 | 24.95 | 24.95 | 23.55 | 24.53 | 37.06K |
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
| Employees | 40 |
| Beta | 0.56 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |